Patents by Inventor Julian Stanley Kroin

Julian Stanley Kroin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted tetralins as selective estrogen receptor-? agonists
    Patent number: 8093302
    Abstract: The present invention relates to novel tetralin ER-? agonist compounds, pharmaceutical compositions thereof, and use of these compounds to treat a ER-? mediated disease such as nocturia, obstructive uropathy, benign prostatic hypertrophy, obesity, dementia, hypertension, incontinence, colon cancer, prostate cancer, infertility, depression, leukemia, inflammatory bowel disease, and arthritis.
    Type: Grant
    Filed: February 10, 2006
    Date of Patent: January 10, 2012
    Assignee: Eli Lilly and Company
    Inventors: Elizabeth Marie Thomas, Bryan Hurst Norman, Julian Stanley Kroin
  • SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS
    Publication number: 20100249075
    Abstract: The present invention relates to novel tetralin ER-? agonist compounds, pharmaceutical compositions thereof, and use of these compounds to treat a ER-? mediated disease such as nocturia, obstructive uropathy, benign prostatic hypertrophy, obesity, dementia, hypertension, incontinence, colon cancer, prostate cancer, infertility, depression, leukemia, inflammatory bowel disease, and arthritis.
    Type: Application
    Filed: February 10, 2006
    Publication date: September 30, 2010
    Applicant: ELI LILLY AND COMPANY
    Inventors: Venkatesh Krishnan, Julian Stanley Kroin, Bryan Hurst Norman, Elizabeth Marie Thomas
  • Methods and compounds for inhibiting MRP1
    Patent number: 6743794
    Abstract: The present invention further relates to a method of inhibiting MRP1 in a mammal which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I).
    Type: Grant
    Filed: May 21, 2002
    Date of Patent: June 1, 2004
    Assignee: Eli Lilly and Company
    Inventors: Rosanne Bonjouklian, Jeffrey Daniel Cohen, Joseph Michael Gruber, Douglas Webb Johnson, Louis Nickolaus Jungheim, Julian Stanley Kroin, Peter Ambrose Lander, Ho-Shen Lin, Mark Christopher Lohman, Brian Stephen Muehl, Bryan Hurst Norman, Vinod Francis Patel, Michael Enrico Richett, Kenneth Jeff Thrasher, Sreenivasarao Vepachedu, Wesley Todd White, Yongping Xie, Jeremy Schulenburg York, Brandon Lee Parkhurst, Qiupang Wang
  • Methods and compounds for inhibiting mrp1
    Publication number: 20030100576
    Abstract: The present invention further relates to a method of inhibiting MRP1 in a mammal which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I).
    Type: Application
    Filed: May 21, 2002
    Publication date: May 29, 2003
    Inventors: Rosanne Bonjouklian, Jeffrey Daniel Cohen, Joseph Michael Gruber, Douglas Webb Johnson, Louis Nickolaus Jungheim, Julian Stanley Kroin, Peter Ambrose Lander, Ho-Shen Lin, Mark Christopher Lohman, Brian Stephen Muehl, Bryan Hurst Norman, Vinod Francis Patel, Michael Enrico Richett, Kenneth Jeff Thrasher, Sreenivasarao Vepachedu, Wesley Todd White, Yongping Xie, Jeremy Schulenburg York, Brandon Lee Parkhurst
  • Drug resistance and multidrug resistance modulators
    Patent number: 6180633
    Abstract: Drug and multidrug resistant modulators of the formula: where R1 and R2 are independently hydrogen or halo; A is —CH2—CH2—, —CH2—CHR4—CH2—, or —CH2—CHR5—CHR6—CH2—, where R4 is —H, —OH, or acyloxy; one of R5 or R6 is —H, —OH, or acyloxy, and the other is —H; R3 is a polyaryl; and pharmaceutically acceptable salts and solvates thereof, are described and claimed. Use of the new compounds in the preparation of pharmaceutical compositions is described and claimed. In addition, methods for treating drug and multidrug resistance in various diseases using a compound, or pharmaceutically acceptable salt or solvate thereof, of this invention are described and claimed.
    Type: Grant
    Filed: June 30, 1999
    Date of Patent: January 30, 2001
    Assignee: Eli Lilly and Company
    Inventors: Julian Stanley Kroin, Bryan Hurst Norman
  • Drug resistance and multidrug resistance modulators
    Patent number: 6130219
    Abstract: Drug and multidrug resistant modulators of the formula: ##STR1## where R.sup.1 and R.sup.2 are independently hydrogen or halo; A is --CH.sub.2 --CH.sub.2 --, --CH.sub.2 --CHR.sup.4 --CH.sub.2 --, or --CH.sub.2 --CHR.sup.5 --CHR.sup.6 --CH.sub.2 --, where R.sup.4 is --H, --OH, or acyloxy; one of R.sup.5 or R.sup.6 is --H, --OH, or acyloxy, and the other is --H; R.sup.3 is a polyaryl; and pharmaceutically acceptable salts and solvates thereof, are described and claimed. Use of the new compounds in the preparation of pharmaceutical compositions is described and claimed. In addition, methods for treating drug and multidrug resistance in various diseases using a compound, or pharmaceutically acceptable salt or solvate thereof, of this invention are described and claimed. Also, methods of enhancing oral bioavailability of a drug and methods of enhancing bioavailability of a drug to the brain using a compound, or pharmaceutically acceptable salt or solvate thereof, of this invention are described and claimed.
    Type: Grant
    Filed: June 30, 1999
    Date of Patent: October 10, 2000
    Assignee: Eli Lilly and Company
    Inventors: Julian Stanley Kroin, Bryan Hurst Norman
  • Drug resistance and multidrug resistance modulators
    Patent number: 6025359
    Abstract: Drug and multidrug resistant modulators of the formula: ##STR1## where R.sup.1 and R.sup.2 are independently hydrogen or halo; A is --CH.sub.2 --CH.sub.2 --, --CH.sub.2 --CHR.sup.4 --CH.sub.2 --, or --CH.sub.2 --CHR.sup.5 --CHR.sup.6 --CH.sub.2 --, where R.sup.4 is --H, --OH, or acyloxy; one of R.sup.5 or R.sup.6 is --H, --OH, or acyloxy, and the other is --H; R.sup.3 is a polyaryl; and pharmaceutically acceptable salts and solvates thereof, are described and claimed. Use of the new compounds in the preparation of pharmaceutical compositions is described and claimed. In addition, methods for treating drug and multidrug resistance in various diseases using a compound, or pharmaceutically acceptable salt or solvate thereof, of this invention are described and claimed. Also, methods of enhancing oral bioavailability of a drug and methods of enhancing bioavailability of a drug to the brain using a compound, or pharmaceutically acceptable salt or solvate thereof, of this invention are described and claimed.
    Type: Grant
    Filed: June 12, 1997
    Date of Patent: February 15, 2000
    Assignee: Eli Lilly and Company
    Inventors: Julian Stanley Kroin, Bryan Hurst Norman
  • Drug resistance and multidrug resistance modulators
    Patent number: 5776939
    Abstract: Drug and multidrug resistant modulators of Formula (C): ##STR1## where Z is selected from the group consisting of --S--, --S(O).sub.w --, and --CH.sub.2 --, where w is 1 or 2; and pharmaceutically acceptable salts or solvates thereof are described and claimed.Use of the new compounds in the preparation of pharmaceutical compositions is described and claimed. In addition, methods for treating drug and multidrug resistance in various diseases using a compound of this invention are described and claimed. Also, methods of enhancing oral bioavailability of a drug and methods of enhancing bioavailability of a drug to the brain using a compound of this invention are described and claimed.
    Type: Grant
    Filed: June 12, 1997
    Date of Patent: July 7, 1998
    Assignee: Eli Lilly and Company
    Inventors: Julian Stanley Kroin, Bryan Hurst Norman